PathWhiz

PathWhiz ID	Pathway	Meta Data
PW127294 View Pathway	disease Xanthinuria Type I Homo sapiens Xanthinuria Type I (Xanthine Dehydrogenase Deficiency) is a condition caused by an autosomal recessive mutation. The condition was discovered (though not diagnosed) in 1817, when stones formed of almost pure xanthine were first identified by Marcet. The symptoms arise because of a malfunction in the production of xanthine oxidase. It is a rare . It is characterized by a loss of oxidase such as in serum and the uric acid found in the urine. This enzyme deficiency causes the accumulation of xanthine in the plasma, hypoxanthine in the serum, and xanthine in the urine. They will be found in the latter and former in increased quantities. Although the condition can cause a wide range of symptoms including renal xanthine stones, what occurs most of the time is that xanthinuria is asymptomatic and diagnosis is product of chance. The disorder has symptoms including arthralgia, hematuria, mental retardation, stomatisis, and urolithiasis. BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Ray Kruger Created On: December 02, 2022 at 11:16 Last Updated: December 02, 2022 at 11:16
PW000489 View Pathway	disease Xanthinuria Type II Homo sapiens Xanthinuria Type II is a rare inborn error of metabolism (IEM) and autosomal recessive disorder and caused by a defective xanthine dehydrogenase. Xanthine dehydrogenase catalyzes the conversion of hypoxanthine into xanthine and conversion of xanthine into uric acid. This disorder is characterized by a large accumulation of xanthine and hypoxanthine; as well as dissipation of uric acid. Symptoms of the disorder include blood in the urine, recurrent urinary tract infections and abdominal pain. It is estimated that xanthinuria types I and II affects 1 in 69,000 individuals. BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: WishartLab Created On: August 29, 2013 at 10:39 Last Updated: August 29, 2013 at 10:39
PW122058 View Pathway	disease Xanthinuria Type II Rattus norvegicus Xanthinuria Type II is a rare inborn error of metabolism (IEM) and autosomal recessive disorder and caused by a defective xanthine dehydrogenase. Xanthine dehydrogenase catalyzes the conversion of hypoxanthine into xanthine and conversion of xanthine into uric acid. This disorder is characterized by a large accumulation of xanthine and hypoxanthine; as well as dissipation of uric acid. Symptoms of the disorder include blood in the urine, recurrent urinary tract infections and abdominal pain. It is estimated that xanthinuria types I and II affects 1 in 69,000 individuals. BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Ana Marcu Created On: September 10, 2018 at 15:51 Last Updated: September 10, 2018 at 15:51
PW121834 View Pathway	disease Xanthinuria Type II Mus musculus Xanthinuria Type II is a rare inborn error of metabolism (IEM) and autosomal recessive disorder and caused by a defective xanthine dehydrogenase. Xanthine dehydrogenase catalyzes the conversion of hypoxanthine into xanthine and conversion of xanthine into uric acid. This disorder is characterized by a large accumulation of xanthine and hypoxanthine; as well as dissipation of uric acid. Symptoms of the disorder include blood in the urine, recurrent urinary tract infections and abdominal pain. It is estimated that xanthinuria types I and II affects 1 in 69,000 individuals. BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Ana Marcu Created On: September 10, 2018 at 15:50 Last Updated: September 10, 2018 at 15:50
PW127298 View Pathway	disease Xanthinuria Type II Homo sapiens Xanthinuria Type II (Xanthine Dehydrogenase Deficiency) is a rare inborn error of metabolism (IEM) and autosomal recessive disorder and caused by a defective xanthine dehydrogenase. Xanthine dehydrogenase catalyzes the conversion of hypoxanthine into xanthine and conversion of xanthine into uric acid. This disorder is characterized by a large accumulation of xanthine and hypoxanthine; as well as dissipation of uric acid. Symptoms of the disorder include blood in the urine, recurrent urinary tract infections and abdominal pain. It is estimated that xanthinuria types I and II affects 1 in 69,000 individuals. BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Ray Kruger Created On: December 03, 2022 at 22:33 Last Updated: December 03, 2022 at 22:33
PW012896 View Pathway	metabolic Xanthophyll Cycle Arabidopsis thaliana Xanthophyll cycle is a pathway that transforms zeaxanthin to violaxanthin and antheraxanthin through enzymes. Xanthophyll cycle mainly takes place in diatoms and dinoflagellates of plants in high-light condition. Zeaxanthin is obatined from zeaxanthin biosynthesis that transforms lycopene to zeaxanthin (indirectly). Zeaxanthin is catalyzed into antheraxanthin and antheraxanthin catalyzed into violaxanthin both by the enzyme, zeaxanthin epoxidase with cofactor FAD. Violaxanthin deepoxidase/antheraxanthin deepoxidase can reverse the above reactions (i.e. violaxanthin to antheraxanthin and antheraxanthin to zeaxanthin). BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Carin Li Created On: February 23, 2017 at 01:47 Last Updated: February 23, 2017 at 01:47
PW012937 View Pathway	metabolic xcaazzz Homo sapiens BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Guest: Anonymous Created On: March 13, 2017 at 04:17 Last Updated: March 13, 2017 at 04:17
PW146158 View Pathway	drug action Xenon Xe-127 Drug Metabolism Action Pathway Homo sapiens BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Ray Kruger Created On: October 07, 2023 at 17:32 Last Updated: October 07, 2023 at 17:32
PW146082 View Pathway	drug action Xenon-133 Drug Metabolism Action Pathway Homo sapiens BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Ray Kruger Created On: October 07, 2023 at 17:22 Last Updated: October 07, 2023 at 17:22
PW122448 View Pathway	drug action Ximelagatran Action Homo sapiens Ximelagatran is a prodrug that is converted to melagatran. This drug is a direct thrombin inhibitor that binds directly to the active site of thrombin, preventing coagulation and formation of blood clots due to the inactivation of the enzyme that catalyzes activation of coagulation factors V, XIII and fibrinogen. Ximelagatran is the first direct thrombin inhibitor that could be taken orally, and was thought to be a replacement for warfarin, due to not having as many dietary restrictions involved. However, it was withdrawn from testing and distribution following evidence of liver damage. After oral administration, ximelagatran is absorbed and converted to melagatran through an unknown series of reactions. From there, melagatran directly binds to thrombin, preventing its use as an enzyme. This prevents catalyzation of factor V to factor Va, which would form the prothrombinase complex and create more thrombin. It also prevents the catalysis fibrinogen or factor I to fibrin, which then polymerizes to form the blood clot. The lack of useable thrombin also prevents the catalysis of factor XIII to factor XIIIa, which is necessary to crosslink the polymerized fibrin to form a water insoluble clot. BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Eponine Oler Created On: April 10, 2019 at 21:07 Last Updated: April 10, 2019 at 21:07